Potential role of 18F-FDG PET/CT in a case of progressive Rosai Dorfman disease

Document Type : Case report


Research Center for Nuclear Medicine, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran


Rosai Dorfman disease is a rare form of nonlangerhans cell histiocytosis, presenting with extensive lymphadenopathies. Treatment in most cases of nodal disease, involves close observation; however, extranodal involvement requires a more definitive treatment strategy. Herein, we report a case of extensive Rosai Dorfman disease in a 43-year-old woman presenting for evaluation of treatment response by 18F-FDG PET/CT after frequent relapses and disease progression. In addition to extensive lymphadenothapies in cervical, supraclavicular, superior mediastinum, axillary, abdominopelvic and inguinofemoral regions, the patient had metabolically active bone and subcutaneous lesions which were not previously recognized. Following this 18F-FDG PET/CT study, the patient management was changed to sirolimus and prednisolone. To choose the best treatment option for Rosai Dorfman patients, knowledge of the full extent of disease is important. Compared with conventional imaging, 18F-FDG PET/CT has the advantage of being a whole-body imaging modality and can recognize disease involvement prior to any anatomical changes.


1. McClain KL, Natkunam Y, Swerdlow SH. Atypical cellular disorders. Hematology. 2004; 2004(1):283-96.
2. Averitt AW, Heym K, Akers L, Castro-Silva F, Ray A. Sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman disease): diagnostic and treatment modalities for this rare entity revisited. J Pediatr Hematol Oncol. 2018; 40(4):e198-e202.
3. Mahajan S, Nakajima R, Yabe M, Dogan A, Ulaner GA, Yahalom J, et al. Rosai-Dorfman Disease—Utility of 18F-FDG PET/CT for Initial Evaluation and Follow-up. Clin Nucl Med. 2020; 45(6):e260-e6.
4. Karunanithi S, Singh H, Sharma P, Naswa N, Kumar R. 18F-FDG PET/CT imaging features of Rosai Dorfman disease: a rare cause of massive generalized lymphadenopathy. Clin Nucl Med. 2014; 39(3):268-9.
5. Mosheimer BA, Oppl B, Zandieh S, Fillitz M, Keil F, Klaushofer K, et al. Bone involvement in Rosai-Dorfman disease (RDD): a case report and systematic literature review. Curr Rheumatol Rep. 2017; 19(5):29.
6. Mantilla JG, Goldberg-Stein S, Wang Y. Extranodal Rosai-Dorfman disease: clinicopathologic series of 10 patients with radiologic correlation and review of the literature. Am J Clin Pathol. 2016; 145(2): 211-21.
7. Foucar E, Rosai J, Dorfman R, editors. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1990; 7(1):19-73.
8. Shaikh F, Awan O, Mohiuddin S, Farooqui S, Khan SA, McCartney W. 18F-FDG PET/CT imaging of extranodal Rosai-Dorfman disease with hepatopancreatic involvementa pictorial and literature review. Cureus. 2015; 7(12).
9. Kong Z, Wang Y, Ma W, Cheng X. FDG PET/CT Image for a Rosai-Dorfman Disease WithPituitary and Bone Involvement in a Pediatric Patient. Clin Nucl Med. 2019; 44(11):873-5.
10. Zhao X, Yu D, Jin C. Three Cases of Extranodal Rosai-Dorfman Disease and Literature Review. Open Life Sciences. 2018; 13(1):263-8.
11. Ocheni S, Ibegbulam O, Okafor O, Raveenthiran V, Nzegwu M. Usefulness of oral corticosteroid in Rosai–Dorfman disease. Eur J Cancer Care. 2007; 16(3):286-8.
12. Sundaram C, Chandrashekar P, Prasad V, Umadevi M. Multifocal osseous involvement as the sole manifestation of Rosai-Dorfman disease. Skeletal Radiol. 2005; 34(10):658-64.
13. Hadchiti J, Kamar FG, Abi Ghosn J, Haidar M, Younes A, Obeid A, et al. 18F-fluoro-2- deoxyglucose positron emission-computed tomography in a rare cutaneous form of Rosai-Dorfman disease: A case report. Mol Clin Oncol. 2018; 8(2):236-41.
14. Shrestha R, Jamison DK, Anene D, Roarke M, Yang M. The Role of 18F-FDG PETCT in the Evaluation and Surveillance of RosaiDorfman Disease. J Nucl Med. 2020; 61(supplement 1):1158.
15. Sandoval-Sus JD, Sandoval-Leon AC, Chapman JR, Velazquez-Vega J, Borja MJ, Rosenberg S, et al. Rosai-Dorfman disease of the central nervous system: report of 6 cases and review of the literature. Medicine. 2014; 93(3): 165-175
16. Adeleye AO, Amir G, Fraifeld S, Shoshan Y, Umansky F, Spektor S. Diagnosis and management of Rosai–Dorfman disease involving the central nervous system. Neurol Res. 2010; 32(6):572-8.
17. Corrigan AJG, Schleyer PJ, Cook GJ, editors. Pitfalls and artifacts in the use of PET/CT in oncology imaging. Semin Nucl Med; 2015: 481-499.
18. Deshayes E, Le Berre J-P, Jouanneau E, Vasiljevic A, Raverot G, Seve P. 18F-FDG PET/CT findings in a patient with isolated intracranial Rosai-Dorfman disease. Clin Nucl Med. 2013; 38(1):e50-e2.
19. Mostardi P, Diehn FE, Rykken J, Eckel L, Schwartz K, Kaufmann TJ, et al. Intramedullary spinal cord metastases: visibility on PET and correlation with MRI features. AJNR Am J Neuroradiol. 2014; 35(1):196-201.
20. Dhull VS, Passah A, Rana N, Kaur K, Tripathi M, Kumar R. 18F-FDG PET/CT of widespread Rosai-Dorfman disease. Clin Nucl Med. 2016; 41(1):57-9.